PHC6059 Introduction to Applied Survival Analysis
Open Researcher and Contributor ID (ORCID)
Areas of Interest
- Clinical Trials Design & Analysis
- Emerging infectious disease
- Infectious Diesease
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
PLOS Medicine. 19(12) [DOI] 10.1371/journal.pmed.1004136. [PMID] 36454733.
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
The Lancet. Infectious diseases. 22(6):791-801 [DOI] 10.1016/S1473-3099(22)00140-2. [PMID] 35366959.
Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study
The Lancet Regional Health – Americas. 1 [DOI] 10.1016/j.lana.2021.100025. [PMID] 34386791.
Risk Factors for Healthcare Personnel Infection With Endemic Coronaviruses (HKU1, OC43, NL63, 229E): Results from the Respiratory Protection Effectiveness Clinical Trial (ResPECT).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 73(11):e4428-e4432 [DOI] 10.1093/cid/ciaa900. [PMID] 32645144.
Analysis of a meningococcal meningitis outbreak in Niger – potential effectiveness of reactive prophylaxis
. [DOI] 10.1101/496299.
Apr 2022 ACTIVE
RAPID: Statistical inference of incidence of SARS-CoV-2 in the US using multiple data streams to identify levels of immunity and the impact of non-pharmaceutical interventions
Role: Co-Project Director/Principal Investigator
Funding: NATL SCIENCE FOU
Mar 2022 ACTIVE
Estimating the incidence of dengue in travelers from non-endemic countries
Funding: Merck Sharp & Dohme
Jan 2022 – Dec 2022
IPA for Matthew Hitchings 2022
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Aug 2021 ACTIVE
Design and Analysis of Vaccine Trials for Emerging Infectious Disease Threats
Funding: EMORY UNIV via NATL INST OF HLTH NIAID